Search results for "BoP"

showing 10 items of 284 documents

Final results of OV16, a phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel (CP) versus CP in first-line chemoth…

2013

5502 Background: Topotecan was evaluated in a novel combination regimen in comparison to standard therapy in front-line EOC. Methods: Women with newly diagnosed advanced EOC stages IIB-IV, ECOG performance status (PS) 0-1, age < 75, were randomized to either Arm 1: cycles 1 - 4: cisplatin 50 mg/m2 d1 plus topotecan 0.75 mg/m2 d1-5 IV; cycles 5 - 8: paclitaxel 175 mg/m2over 3 hrs d1 followed by carboplatin AUC5 day 1 or Arm 2: paclitaxel plus carboplatin as in Arm 1 for 8 cycles. The primary endpoint was progression free survival (PFS) and secondary endpoints included objective response, overall survival (OS), adverse event (AE) and Quality of Life (QoL). The sample size required 800 pts…

GynecologyOncologyCancer Researchmedicine.medical_specialtybusiness.industryCarboplatin/paclitaxellaw.inventionRegimenOncologyRandomized controlled triallawCisplatin/topotecanInternal medicinemedicineTopotecanEpithelial ovarian cancerFirst line chemotherapybusinessStandard therapymedicine.drugJournal of Clinical Oncology
researchProduct

Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice

2013

Epithelial ovarian cancer (EOC) is the sixth most common malignancy in women. Ovarian tumors consist of several clinical and pathological entities that share an anatomic site. The gold standard treatment, both in front-line and in adjuvant setting, is represented by carboplatin/paclitaxel combination. Conversely, the second-line treatment is not well defined. The response to platinum is the major prognostic factor for survival. In this review we discuss the current views on platinum-refractory/resistant patient treatment only, which includes patients progressing or relapsing within 6 months from the last platinum-based course. Concerning this subgroup, the activity of several conventional d…

GynecologyOncologymedicine.medical_specialtyendocrine system diseasesBevacizumabtarget therapybusiness.industrymedicine.medical_treatmentGold standardbevacizumabmedicine.diseaseMalignancyCarboplatinchemistry.chemical_compoundovarian cancerPaclitaxelchemistryInternal medicinemedicineplatinumbusinessOvarian cancerPathologicalAdjuvantmedicine.drugJournal of Cancer Therapy
researchProduct

Budd-Chiari Syndrom – eine seltene Manifestation der hereditären Thrombophilie

2000

Das Budd-Chiari Syndrom ist eine seltene Manifestationsform der hereditaren oder erworbenen Thrombophilie. Bei einer 30 jahrigen Patientin konnte, nach anfanglichen diagnostischen Schwierigkeiten, ein BCS diagnostiziert und erfolgreich, durch portocavalen Seit-zu-Seit Shunt, behandelt werden. Bei der Chiari-Trias aus abdominellen Schmerzen, Hepatomegalie und Ascites mus das BCS in die differentialdiagnostischen Uberlegungen mit einbezogen und gegebenenfalls durch invasive Diagnostik ausgeschlossen werden. Therapiemoglichkeiten sind die Anticoagulation und die Anlage eines portosystemischen Shunts (TIPS oder chirurgischer Shunt). Eine Lebertransplantation kommt als ultima ratio bei Leberinsu…

Gynecologymedicine.medical_specialtyTransplant surgerybusiness.industryCardiothoracic surgeryHereditary thrombophiliaBudd–Chiari syndromeMedicineSurgeryVascular surgerybusinessmedicine.diseaseAbdominal surgeryDer Chirurg
researchProduct

Prothrombinase-Induced Clotting Time Assay for Determination of the Anticoagulant Effects of Unfractionated and Low-Molecular-Weight Heparins, Fondap…

2008

The prothrombinase-induced clotting time assay (PiCT, Pentapharm, Basel, Switzerland) is a clotting assay sensitive to factor Xa and factor IIa inhibitors. It is based on the addition of factor Xa and snake venom RVV-V (Russell viper venom factor V activator) specifically activating factor V and phospholipids to platelet-poor plasma. Following an incubation time, the mixture is recalcified and the clotting time is determined. An almost linear dose-response and high sensitivity of the assay for unfractionated heparin (UFH), low-molecular-weight heparins (LMWHs), r-hirudin, and argatroban was found. Fondaparinux showed a nonlinear dose-response. By using ex vivo samples, the following Pearson…

HeparinChemistryHirudinGeneral MedicineHeparin Low-Molecular-WeightPharmacologyFondaparinuxSensitivity and SpecificityFondaparinux SodiumArgatrobanThromboplastinThrombinFibrinolytic AgentsFondaparinuxBiochemistryClotting timePolysaccharidesProthrombinasemedicineHumansBlood Coagulation Testsmedicine.drugDiscovery and development of direct thrombin inhibitorsAmerican Journal of Clinical Pathology
researchProduct

<p class="HeadingRunIn"><strong>Reinterpretation of the enigmatic Ordovician genus <em>Bolboporites </em>(Echinodermata)</…

2019

Bolboporites is an enigmatic Ordovician cone-shaped fossil, the precise nature and systematic affinities of which have been controversial over almost two centuries. For the first time, a wide range of techniques (CT-scan, SEM, cathodoluminescence, XPL, UV epifluorescence, EBSD, FT-IR and XRF spectrometry) were applied to well-preserved specimens of Bolboporites from Norway and Russia. Our main finding confirms its echinoderm affinities, as shown by its stereomic microstructure and by the first definitive evidence of its monocrystalline nature. Each cone consists in a single, microporous calcitic crystal with a narrow longitudinal internal canal. These results are combined with all previous …

HoldfastSpine (zoology)AppendagePaleontologybiologyEchinodermGenusOrdovicianBolboporitesbiology.organism_classificationAffinitiesGeologyZoosymposia
researchProduct

Hypersensibilité immédiate au carboplatine ou à l’oxaliplatine : réintroduction du cisplatine sans tests cutané ?

2017

International audience; Introduction : L’incidence des réactions d’hypersensibilité immédiate aux sels de platine (cisplatine, carboplatine et oxaliplatine) augmente avec leur large utilisation en cancérologie. Les objectifs de cette étude étaient d’établir la fréquence des sensibilités croisées entre les sels de platine, de déterminer si le cisplatine peut être utilisé sans test allergologique préalable en cas d’allergie immédiate au carboplatine ou à l’oxaliplatine et enfin de proposer une prise en charge simple pour retraiter rapidement les malades.Méthodes : Notre étude rétrospective a porté sur 155 malades ayant présenté une réaction d’hypersensibilité immédiate à un sel de platine. De…

Hypersensibilité allergiqueCarboplatine[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract3. Good health030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicine030228 respiratory systemSels de platineImmunology and Allergy[ SDV.MHEP.DERM ] Life Sciences [q-bio]/Human health and pathology/DermatologyOxaliplatine[ SDV.MHEP.PSR ] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
researchProduct

CD248 enhances tissue factor procoagulant function, promoting arterial and venous thrombosis in mouse models

2021

BACKGROUND: CD248 is a pro-inflammatory, transmembrane glycoprotein expressed by vascular smooth muscle cells (VSMC), monocytes/macrophages, and other cells of mesenchymal origin. Its distribution and properties are reminiscent of those of the initiator of coagulation, tissue factor (TF). OBJECTIVE: We examined whether CD248 also participates in thrombosis. METHODS: We evaluated the role of CD248 in coagulation using mouse models of vascular injury, and by assessing its functional interaction with the TF-factor VIIa (FVIIa)-factor X (FX) complex. RESULTS: The time to ferric chloride-induced occlusion of the carotid artery in CD248 knockout (KO) mice was significantly longer than in wild-typ…

InflammationFactor VIIa030204 cardiovascular system & hematologyInferior vena cavaArticleThromboplastin03 medical and health sciencesTissue factorchemistry.chemical_compoundMice0302 clinical medicineThrombinTissue factor pathway inhibitorAntigens CDAntigens NeoplasmmedicineAnimalsHumansMice KnockoutVenous Thrombosismedicine.diagnostic_testFactor XHematologyCoagulationchemistrymedicine.veinCancer researchProthrombin Timemedicine.symptommedicine.drugPartial thromboplastin time
researchProduct

CiC3-1a-Mediated Chemotaxis in the Deuterostome Invertebrate Ciona intestinalis (Urochordata)

2003

Abstract Deuterostome invertebrates possess complement genes, and in limited instances complement-mediated functions have been reported in these organisms. However, the organization of the complement pathway(s), as well as the functions exerted by the cloned gene products, are largely unknown. To address the issue of the presence of an inflammatory pathway in ascidians, we expressed in Escherichia coli the fragment of Ciona intestinalis C3-1 corresponding to mammalian complement C3a (rCiC3-1a) and assessed its chemotactic activity on C. intestinalis hemocytes. We found that the migration of C. intestinalis hemocytes toward rCiC3-1a was dose dependent, peaking at 500 nM, and was specific for…

Lipopolysaccharidescomplement system ascidiansHemocytesMolecular Sequence DataIn situ hybridizationPertussis toxinimmunologyHemolymphEscherichia coliAnimalsImmunology and AllergyCiona intestinalisAmino Acid SequencePeptide sequenceinnate immunityInflammationCell-Free SystemChemotactic FactorsbiologyImmune SeraRiboprobeChemotaxisAnatomybiology.organism_classificationRecombinant ProteinsComplement systemCell biologyCiona intestinalisChemotaxis LeukocyteHemocyte migrationPertussis ToxinCell Migration InhibitionComplement C3a
researchProduct

Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia

2012

Eltrombopag is an oral thrombopoietin-receptor agonist. This study evaluated the efficacy of eltrombopag for increasing platelet counts and reducing the need for platelet transfusions in patients with thrombocytopenia and chronic liver disease who are undergoing an elective invasive procedure.We randomly assigned 292 patients with chronic liver disease of diverse causes and platelet counts of less than 50,000 per cubic millimeter to receive eltrombopag, at a dose of 75 mg daily, or placebo for 14 days before a planned elective invasive procedure that was performed within 5 days after the last dose. The primary end point was the avoidance of a platelet transfusion before, during, and up to 7…

Liver CirrhosisMaleCirrhosisChronic liver diseaseBenzoateslaw.inventionchemistry.chemical_compoundRandomized controlled triallawReceptorsClinical endpoint80 and overMedicineCIRRHOSISAged 80 and overBenzoic AcidsGeneral MedicineCHRONIC LIVER DISEASEMiddle AgedHydrazinesThrombopoietinElective Surgical ProceduresAnesthesiaFemaleElective Surgical ProcedureReceptors ThrombopoietinAdultAdolescentEltrombopagELTROMBOPAGHemorrhagePlatelet TransfusionPlaceboYoung AdultDouble-Blind MethodElectiveSurgical Procedures ElectiveHumansAgedTHROMBOCYTOPENIA; ELTROMBOPAG; CIRRHOSIS; CHRONIC LIVER DISEASESurgical Proceduresbusiness.industryPlatelet CountTHROMBOCYTOPENIAcirrhosisSettore MED/09 - MEDICINA INTERNAmedicine.diseaseThrombocytopeniaPlatelet transfusionchemistryChronic DiseasePyrazolesbusiness
researchProduct

12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombo…

2015

Background: A 24-48-week course of interferon-based therapy poorly tolerated in hepatitis C virus (HCV) cirrhosis patients with thrombocytopenia. Aim of the study was to identify patients at low-risk of liver-related complications over a 12-week course of interferon-based therapy. Methods: We assessed the rate of complications and death during the first 12 weeks of interferon-based therapy in HCV cirrhotics with thrombocytopenia (platelets ≤75×109/L) enrolled in the ENABLE-1 and -2 phase 3 randomised controlled trials. Results: Overall, among 1441 patients, 89 complications (6.9%) and 10 deaths (0.7%) were observed within the first 12 weeks of therapy. At univariate analysis baseline albumi…

Liver CirrhosisMaleCirrhosisHepacivirusmedicine.disease_causeGastroenterologyBenzoatesSeverity of Illness IndexLiver-related complicationchemistry.chemical_compoundModel for End-Stage Liver DiseaseRisk FactorsAlbumin levelHydrazineMultivariate AnalysiAged 80 and overUnivariate analysisGastroenterologyHepatitis CMiddle AgedHydrazinesTreatment OutcomeFemaleHumanAdultmedicine.medical_specialtyLiver CirrhosiHepatitis C virusEltrombopagAlpha interferonAntiviral AgentsBenzoateInternal medicineAlbuminsRibavirinmedicineHumansLiver-related mortalityAgedAntiviral AgentHepaciviruHepatologybusiness.industryAlbuminRisk FactorRibavirinMELD scoreInterferon-alphaHepatitis C Chronicmedicine.diseaseThrombocytopeniaSurgerychemistryPyrazoleMultivariate AnalysisPyrazolesbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct